Nirav Shah, MD, on the Potential of Dual-Targeted CAR-T in Chronic Lymphocytic Leukemia

Commentary
Video

The associate professor of medicine at Medical College of Wisconsin discussed clinical results from patients with CLL and Richter’s transformation treated with CD19/CD20-targeted CAR-T LV20.19.

“There are lots of other groups doing dual-targeted CARS and so I think we really need to learn: What is the best next CAR-T? We're really happy with CD19-targeted CAR-T in blood cancers. It's clearly saved lives—but we can do better. So is it a CD20/CD19 CAR? Is it a CD22/CD19 CAR? Is it a combination of all of these? Lots of different groups are working on figuring out that perfect combination to really get the best outcome possible.”

LV20.19 is a bispecific CD19/CD20-targeting chimeric antigen receptor T-cell (CAR-T) therapy currently being evaluated for the treatment of patients with hematological malignancies in a phase 1/2 clinical trial (NCT04186520). Notably, the trial its treating patients with relapsed/refractory chronic lymphocytic leukemia (CLL), including patients with Richter’s transformation (RT). Results from patients with CLL and RT were recently reported in an oral presentation at the 2024 Tandem Meetings |Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, held in San Antonio, Texas, February 21-24, 2024, by principal investigator Nirav Shah, MD, an associate professor of medicine at Medical College of Wisconsin.

Following his presentation, CGTLive® sat down with Shah to talk about the results and their implications. Shah highlighted the promising efficacy findings, pointing out that the CAR-T demonstrated an overall response rate in the realm of 70% to 80%. In terms of safety, he noted that LV20.19 showed a toxicity referred to as immune effector cell hemophagocytic lymphohistiocytosis like syndrome (IEC-HS), which is unique to the CAR-T construct and primarily occurred in the patients with CLL. He stated that patients with CLL treated in the trial going forward will receive a modified dose level with the intention of ameliorating IEC-HS.

Shah also discussed how bispecific approaches to CAR-T in general may provide better outcomes than monospecific approaches to CAR-T, and as such research on bispecific CAR-T therapies will continue to be of great interest in the future. He concluded with a message to the clinical community that the trial for LV20.19 is still recruiting and may be of particular interest as it is one of the few active CAR-T trials for patients with CLL.

REFERENCES
1. Shah NN, Atallah EL, Abedin S, et al. Phase 1 trial of LV20.19 CAR T-cells for relapsed, refractory CLL and Richter’s transformation. Presented at: 2024 Tandem Meetings, February 21-24, San Antonio, Texas. Abstract #40
Related Videos
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Frederick “Eric” Arnold, PhD
Genovefa (Zenia) Papanicolaou, MD, an infectious diseases specialist at Memorial Sloan Kettering Cancer Center
Jeffrey Chamberlain, PhD, on Exciting New Research at MDA 2024
Alan Beggs, PhD, on Challenges in Therapeutic Development for Rare Diseases
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
PJ Brooks, PhD
© 2024 MJH Life Sciences

All rights reserved.